Randall Dere

Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

Maria Corinna Palanca-Wessels, Myron S. Czuczman, Gilles Salles et al. · The Lancet Oncology · 2015 · 326 citations

Lymphoid Neoplasia, Chronic Lymphocytic Leukaemia, Medicine +9

Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status

Michael S. Gordon, Daniela Matei, Carol Aghajanian et al. · Journal of Clinical Oncology · 2006 · 249 citations

Bioanalytical Assay Strategies for The Development of Antibody–Drug Conjugate Biotherapeutics

Surinder Kaur, Keyang Xu, Ola M. Saad et al. · Bioanalysis · 2013 · 227 citations

Immunocytochemical Technique, Immunology, Immunotherapeutics +19

Characterization of The Drug-To-Antibody Ratio Distribution for Antibody–Drug Conjugates in Plasma/Serum

Keyang Xu, Luna Liu, Randall Dere et al. · Bioanalysis · 2013 · 105 citations

Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma

Andrew G. Polson, Marna Williams, Aimee Gray et al. · Leukemia · 2010 · 88 citations

Lymphoid Neoplasia, Medicine, Antibody-drug Conjugate +8